The vaccines business of the sanofi-aventis Group (NYSE: SNY; EPA: SAN) - Sanofi pastuer (8788819) - has bagged a contract with the Office of Public Health and Emergency Preparedness (a division of the U.S. Department of Health and Human Services) for the production of bulk concentrate of a new type of H5N1 pre-pandemic vaccine.
While previous stockpile contracts covered the clade 1 form of the H5N1 virus, this particular contract covers clade 2 of the H5N1 virus (A/Indonesia) for use in the U.S. government stockpile.
The bulk concentrate is currently being produced while the agreement is initially valued at up to $117.9 million, the final value of which is dependent on the number of doses that can be formulated from the bulk material.
Find more details from the press release (a pdf file).
Comment Preview